{"id":"W2313477739","doi":"10.1097/yic.0000000000000105","title":"A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan","year":2015,"lang":"en","type":"article","venue":"International Clinical Psychopharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Global Affairs Canada","funders":"Eli Lilly Japan; Meiji Seika Pharma; Shionogi; Pfizer Japan; Abbott Japan; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; AbbVie; Novartis Pharma; Otsuka Pharmaceutical; Eisai; Astellas Pharma; GlaxoSmithKline Japan; Kyowa Hakko Kirin; Pfizer; Dainippon Sumitomo Pharma; Boehringer Ingelheim Japan; Astellas Foundation for Research on Metabolic Disorders; GlaxoSmithKline; FP Pharmaceutical Corporation; Bristol-Myers Squibb; Eli Lilly and Company; MSD K.K.; Asahi Kasei Pharma Corporation","keywords":"Venlafaxine; Placebo; Major depressive disorder; Medicine; Term (time); Randomized controlled trial; Immediate release; Anesthesia; Venlafaxine Hydrochloride; Internal medicine; Psychiatry; Pharmacology; Antidepressant; Anxiety; Physics; Alternative medicine; Mood","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002467067,0.0002642115,0.001166722,0.000222179,0.00005754163,0.00001718379,0.000195031,0.00008586301,0.00003923991],"category_scores_gemma":[0.001838813,0.0001459392,0.0001183619,0.0001220253,0.0002086517,0.0000768796,0.000166402,0.000293469,0.000003972993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005415051,"about_ca_system_score_gemma":0.00007899739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004496237,"about_ca_topic_score_gemma":0.0001177467,"domain_scores_codex":[0.9965251,0.000848385,0.00118014,0.0006690862,0.0005652395,0.0002120638],"domain_scores_gemma":[0.9949266,0.003546882,0.000358047,0.0002957475,0.0006107293,0.0002619452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5577672,0.01222301,0.4249895,0.000007579597,0.0009184379,0.00002348937,0.0004243272,0.00002939368,0.00001422358,0.000003448044,0.00006921281,0.003530236],"study_design_scores_gemma":[0.5199859,0.004941624,0.4737166,0.00005273637,0.0008539876,0.000005257129,0.0001120005,0.000218148,0.000002426772,0.00003062777,0.00000739468,0.00007329985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766648,0.0002233309,0.00008775489,0.001865685,0.0006829361,0.02039755,0.00001332671,0.00001939702,0.00004519654],"genre_scores_gemma":[0.9975825,0.00004434031,0.0001265212,0.0003874834,0.0001421608,0.001553529,0.00002170164,0.0000298171,0.0001119392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04872714,"threshold_uncertainty_score":0.5951228,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05728496281993833,"score_gpt":0.4471914282007698,"score_spread":0.3899064653808315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}